We aimed to assess the accuracy of measuring serum or plasma (1/3)-b-D-glucan (BDG) for the diagnosis of invasive fungal infections (IFIs) by means of a meta-analysis of relevant studies. We searched in bibliographic databases for relevant cohort or case-control studies. We primarily compared BDG between patients with proven or probable IFIs (excluding Pneumocystis jirovecii infections), according to the criteria of the European Organization for Research and Treatment of Cancer/Mycoses Study Group or similar criteria, and patients without IFIs (excluding healthy individuals as controls). A total of 2979 patients (594 with proven or probable IFIs), included in 16 studies, were analyzed. The pooled sensitivity of BDG was 76.8% (95% confidence interval [CI], 67.1%-84.3%), and the specificity was 85.3% (95% CI, 79.6%-89.7%). The area under the summary receiver operating characteristic curve was 0.89. Marked statistical heterogeneity was noted. BDG has good diagnostic accuracy for distinguishing proven or probable IFIs from no IFIs. It can be useful in clinical practice, if implemented in the proper setting and interpreted after consideration of its limitations.
Invasive fungal infections (IFIs) comprise a rather heterogeneous group of yeast and mold infections [1] . They have acquired increasing clinical importance because of an increase in the population at risk, which generally includes patients with disease-related or iatrogenic immunosuppression [2, 3] and patients dependent on various types of supportive care [4, 5] . Despite the advent of novel antifungal agents [6] , the mortality rate associated with IFIs is considerably high [7] . Early administration of antifungal therapy is important in this regard, yet a definitive diagnosis of IFI often cannot be made promptly, as this may require the use of invasive procedures [8] . Many patients with clinical suspicion for the presence of an IFI are treated empirically with antifungal therapy that may involve the unnecessary use of potentially toxic and costly drugs.
There is increasing interest in preemptive antifungal therapy, which is defined as treatment that is deferred until there is substantial evidence for the presence of an IFI [9] . Early detection of diagnostic markers of a fungal infection, such as fungal nucleic acids, antigens, antibodies, or cell wall components, is essential in this regard [10, 11] . The main relevant example is the use of galactomannan in the diagnosis of invasive aspergillosis [12, 13] . Another serum marker for the presence of IFIs is (1/3)-b-D-glucan (BDG), which has been included in the relevant European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/ MSG) diagnostic criteria [12] .
BDG is a component of the cell wall of most fungi. The main exceptions are Zygomycetes and cryptococci, which release no or little BDG to be detected in human serum [14] . The measurement of BDG is based on the Limulus test [15] . BDG activates factor G, a serine protease zymogen of the Limulus amebocyte lysate, which is extracted from amebocytes of horseshoe crab species. This in turn activates a coagulation cascade. The activity of this reaction can be measured with use of colorimetric or turbidimetric methods. We aimed to evaluate the diagnostic accuracy of this test by performing a meta-analysis of data extracted from relevant studies.
METHODS

Study Selection
We searched in PubMed and Scopus (Health Sciences subject area) for records through February 2010 and in the Cochrane Library for records through April 2010 of studies that evaluated the diagnostic performance of serum or plasma BDG for IFIs. The search terms used were ''glucan AND infection'' for PubMed and Scopus and ''glucan OR beta-glucan'' for the Cochrane Library. We also hand-searched the bibliographies of relevant articles. We selected for inclusion studies that, using diagnostic criteria that were in accordance with the 2002 or 2008 relevant EORTC/MSG criteria [12, 16] , compared patients with IFIs with patients without IFIs. We excluded studies that were presented only as abstracts at scientific conferences, included fewer than 10 cases of IFI, or were published in languages other than English, Spanish, German, French, Italian, or Greek.
Data Extraction
From each of the included studies, we extracted data regarding the study design, characteristics of the patients studied, criteria used for the diagnosis of IFI, types of IFI included, assay used for BDG detection, strategy followed for BDG sampling, and administration of antifungal therapy. We also extracted patient data regarding the number of true-and false-positive and trueand false-negative results obtained with the BDG assay. Where such data were not specifically reported, we calculated them from the related data on sensitivity and specificity and positive and negative predictive value with use of known mathematical formulas. We also extracted specific data regarding the sensitivity of BDG specifically for diagnosis of invasive infections caused by Candida or Aspergillus.
Quality Assessment of the Included Studies
The methodological quality of the included studies was assessed with the QUADAS tool [17] . Eight of the 14 QUADAS items were considered relevant for our meta-analysis. The spectrum of patients included in a study was considered to be representative of the target population if they had an IFI or were at risk for developing an IFI. The acceptable reference standard consisted of diagnostic criteria matching the 2002 or 2008 EORTC/MSG relevant criteria [12, 16] . Partial and differential verification bias was considered to have been avoided if all the included patients were assessed with the same reference standard. Incorporation bias was considered to have been avoided if the diagnosis of IFI was established regardless of the BDG test result. The RevMan software, version 5, was used to plot the output data of the methodological quality assessment [18] .
Data Analysis
To evaluate the diagnostic performance of BDG testing for IFI, we performed 2 comparisons. First, we performed a proof-ofconcept comparison evaluating the performance of BDG assays for case patients with proven IFIs compared with control patients without IFIs. In our main comparison, case patients with proven or probable IFIs were compared with control patients without IFIs. We did not include data on patients with Pneumocystis jirovecii infection. We also did not include data on healthy individuals. We excluded data on patients with possible IFIs from our analysis. For studies that did not report specific data to allow for the exclusion of these patients, we considered such patients to be control patients if they made up ,15% of the total control group.
We did not exclude any study from the analysis on the basis of the BDG assay used. We included in the analysis diagnostic data referring to the BDG cutoff level used in each study. If a study reported BDG data for different cutoff values, we selected for inclusion those referring to a cutoff of 80 pg/mL for the Fungitell or Glucatell assay, 30 pg/mL for the Fungitec G-Test MK, 20 pg/mL for the (Fungitec) G-Test [19] , and 11 pg/mL for the Wako b-Glucan assay, which were considered to be equivalent [19, 20] . If a study reported BDG data obtained with different sampling strategies, we included those for which a positive test result was defined by 1 positive BDG value. Subgroup analyses were performed on studies using the same or similar BDG assays.
We performed a diagnostic test meta-analysis regarding the performance of BDG testing for the diagnosis of IFIs. We calculated the pooled sensitivity and specificity, positive and negative likelihood ratios, and the diagnostic odds ratio of BDG, along with the respective 95% confidence intervals (CIs), using a bivariate meta-analysis model [21] . We constructed a hierarchical summary receiver operating characteristic (HSROC) curve plotting sensitivity versus specificity and calculated the area under the curve [22] . We evaluated the degree of interstudy statistical heterogeneity using the I 2 test [23] . We evaluated the presence of a threshold effect on the accuracy of the BDG with the Spearman correlation coefficient between the logits of sensitivity and specificity. For all the above analyses we used the Midas module in the Stata software, version r.10 (StataCorp) [24, 25] .
testing for the diagnosis of IFIs [19, 20, . The process of selection of studies that were eligible for inclusion is shown graphically in Figure 1 .
In Table 1 , we present the characteristics of the 23 studies included in our review, and in Table 2 , the data on the diagnostic performance of BDG assays for IFIs that we extracted from each of the included studies, according to our prespecified criteria. Among the 23 reviewed studies, 16 were eligible for inclusion in the meta-analysis [19, 20, 26-29, 31-33, 35, 37-39, 41, 43, 46] . The remaining 7 studies were not included in the meta-analysis, because they used healthy individuals as controls [34, 36, 40, 44, 45] , included patients with possible IFIs as case patients [30] , or provided data only for sample-based BDG analysis [42] . We present data from these 7 studies, with regard to their characterstics and the diagnostic performance of BDG, in Tables  1 and 2. Among the 16 studies included in the meta-analysis, 10 had a cohort study design [19, 20, 26, 28, 29, 32, 33, 39, 41, 46] , and the remaining 6 had a case-control design (Table 1) [27, 31, 35, 37, 38, 43] . Eleven studies evaluated mainly (.50%) patients with hematological malignancy or other serious hematological disease [19, 20, 26-28, 31, 32, 37, 39, 41, 46] , whereas the remaining 5 studies evaluated hospitalized patients who primarily had systemic Candida infections [29, 35, 38] , had received liver transplants [33] , or had miscellaneous underlying diseases [43] .
Four of the 16 studies used the Fungitell assay [27, 28, 31, 38] , and 3 studies used the Glucatell assay [20, 29, 37] ; these are the NOTE. ICU, intensive care unit; I(P)A, invasive (pulmonary) aspergillosis; NA, nonanalyzed (see text); NR, not reported; Same, same data as for proven/probable IFIs; 1, positive; -, negative. a The adjusted cutoff was calculated by dividing the BDG cutoff selected from each of the included studies by 80 for the Glucatell/Fungitell assay, 30 for the Fungitec G-test MK, 20 for the (Fungitec) G-test, 11 for the Wako b-Glucan test, and by the actual cutoff used for the other assays (see text for details).
b Data for proven IFIs are for a cutoff of 7 pg/mL and 2 consecutive positive values required for positivity.
commercial and the research version, respectively, of the same assay marketed by Associates of Cape Cod. Four other studies used BDG assays developed by Seikagaku Corporation (the parent company of the one above), namely, the Fungitec G-Test MK [19] , Fungitec G-Test [33] , Fungi-Tec [41] , and G-Test [46] . All 11 assays listed above are colorimetric. Four studies used assays developed by Wako Pure Chemicals Industries-turbidimetric assays in 3 studies [35, 39, 43 ] and a colorimetric assay in 1 study [32] . One study used the GKT-5M Set Kinetic Fungus Detection Kit, another turbidimetric BDG assay [26] .
Various cutoff levels for the definition of a positive BDG test result were used in the 16 included studies ( Table 2) . Eleven studies required at least 1 positive BDG value in cases in which multiple samples per patient were measured [20, 26, 32, 33, 35, 37-39, 41, 43, 46] ; 4 studies required a single positive BDG value for a specific measurement [19, 28, 29, 31] ; and 1 study required 2 consecutive positive BDG values [27] .
In 7 of the analyzed studies, more than 50% of the patients received antifungal therapy before BDG sampling or IFI diagnosis (Table 1) [19, 20, 26, 27, 33, 39, 41] . In 5 studies, fewer than 50% of the patients received such therapy [28, 31, 32, 35, 37] , whereas no specific relevant information was clearly reported in the remaining 4 studies [29, 38, 43, 46] . Figure 2 presents our assessment of whether each of the 23 studies included in our review satisfied the 8 items of the QUADAS tool that were considered relevant to our review. Figure 3 summarizes the findings of our methodological quality assessment for all 23 studies cumulatively.
Methodological Quality of the Included Studies
Diagnostic Accuracy of BDG Measurement (Patients with Proven IFIs)
Fourteen studies provided specific data regarding the measurement of BDG for case patients with proven IFIs (n 5 365) and control patients without IFIs (n 5 2253) [19, 20, 27-29, 31-33, 35, 37, 39, 41, 43, 46] . The pooled sensitivity of BDG was 79.1% (95% CI, 68.9%-86.7%), and the specificity was 87.7% (95% CI, 82.4%-91.6%). The pooled diagnostic odds ratio was 27.0 (95% CI, 13.8-52.8), the positive likelihood ratio was 6.4 (95% CI, 4.4-9.4), and the negative likelihood ratio was 0.24 (95% CI, 0.16-0.37). The area under the HSROC curve for BDG was 0.91 (95% CI, 0.88-0.93). High interstudy heterogeneity was noted; the I 2 index was 92% (95% CI, 84%-99%).
Diagnostic Accuracy of BDG Measurement (Patients with Proven or Probable IFIs)
The 16 studies included in our main analysis evaluated a total of 2979 patients (594 patients with proven or probable IFIs and 2385 patients without IFIs). The pooled sensitivity of BDG testing for the diagnosis of IFIs was 76.8% (95% CI, 67.1%-84.3%), and the specificity was 85.3% (95% CI, 79.6%-89.7%) ( Figure 4 ). The pooled diagnostic odds ratio was 19.2 (95% CI, 10.5-35.4), the positive likelihood ratio was 5.2 (95% CI, 3.7-7.5), and the negative likelihood ratio was 0.27 (95% CI, 0.19-0.40). The area under the HSROC curve for BDG was 0.89 (95% CI, 0.86-0.91) ( Figure 5 ). The I 2 index of Figure 2 . Methodological quality assessment of each of the 23 reviewed studies according to 8 QUADAS criteria. A positive sign denotes that a study meets the criteria, and a negative sign denotes that a study does not meet the criteria. A blank cell denotes that no adequate relevant data were provided.
heterogeneity was 95% (95% CI, 91%-99%). There was a weak negative correlation between the logits of sensitivity and specificity (Spearman correlation coefficient, 20.09), indicating the absence of an important effect of the diagnostic threshold (cutoff level) on the performance of BDG measurement.
Subgroup Analyses
Seven studies used either the Fungitell or Glucatell assay for the measurement of BDG [20, 27-29, 31, 37, 38] . The pooled sensitivity of BDG testing for the diagnosis of IFIs was 71.3% (95% CI, 59.9%-80.6%), and the pooled specificity was 82.0% (95% CI, 69.6%-90.1%). The pooled diagnostic odds ratio was 11.3 (95% CI, 4.7-27.5), the positive likelihood ratio was 4.0 (95% CI, 2.2-7.2), and the negative likelihood ratio was 0.35 (95% CI, 0.24-0.52). The area under the HSROC curve was 0.81 (95% CI, 0.78-0.85). The I 2 index was 85% (95% CI, 70%-100%).
BDG Measurement for Patients with Candida or Aspergillus Infection
Of the 23 overall included studies, 11 provided specific data regarding the sensitivity of BDG testing for both patients with invasive aspergillosis and patients with systemic Candida infections [19, 20, 27, 28, 31-33, 36, 43-45] . As can be inferred from Table 3 , the performance of BDG testing for the detection of systemic Candida infection did not differ considerably from its performance for the detection of invasive aspergillosis.
BDG Measurement for Patients with Possible IFIs and for Healthy Individuals
Five of the studies included in our review reported specific BDG data for patients with possible cases of IFI [20, 32, 34, 37, 39] . They included a total of 130 BDG results for such cases (range, 3-51 results), and the average rate of BDG positivity was 27.7% (range, 3%-51%). Eight of the studies reported BDG data for healthy individuals [31, 34, 38, 40, [43] [44] [45] [46] . They included a total of 310 BDG results for such individuals (range, 10-92 results), and the average rate of BDG positivity was 1.0%. All 3 positive results were observed in a single study with 40 healthy controls [31] .
DISCUSSION
The main finding of our meta-analysis is that serum BDG measurement has good diagnostic accuracy for IFIs diagnosed in accordance with the EORTC/MSG or similar criteria. In our main analysis comparing patients who had proven or probable IFIs with patients who did not have IFIs, the area under the HSROC curve was 0.89; a value between 0.80 and 0.90 has traditionally been considered to indicate good diagnostic test accuracy. The sensitivity of BDG measurement seems to be lower than the specificity, 77% compared with 85%. However, the above findings should be interpreted in light of the high statistical heterogeneity that we noted among the included studies for all analyses.
Potential sources of heterogeneity among the included studies are differences in study design, characteristics of the study population, type of pathogens evaluated, assay and cutoff level used, sampling method and definition of a positive test result, and prior administration of antifungal therapy [47] . The latter parameter might be important, because prior antifungal therapy can decrease the sensitivity of galactomannan [48] and-of particular relevance to the measurement of BDG-ecchinocandins act by inhibiting BDG synthesis.
The studies included in our meta-analysis evaluated various categories of patients. We excluded data on healthy individuals used as controls, because they are not representative of the population to which the test will be applied in clinical practice. Of note, BDG tended to yield negative results for almost all of the healthy controls included in the various studies. Their inclusion would therefore have caused an overestimate of the diagnostic accuracy of BDG testing [13] .
We did not observe a considerable difference in the sensitivity of BDG testing for the detection of invasive Candida or Aspergillus infections. Some studies included IFIs caused by cryptococci or Zygomycetes, but they constituted a small minority of all IFIs evaluated [19, 27, 28, 33, 43] , and BDG values were not always negative, particularly for infections due to cryptococci, which can release small amounts of BDG [19] . We did not include patients with P. jirovecii infections in this meta-analysis, which should be evaluated in the context of positive BDG results [19, 28, 31] .
The available BDG assays differ in many aspects, such as the measurement method (colorimetric or turbidimetric), the horseshoe crab species used, the type of b-glucan used as standard, the The straight line represents the curve; the diamond represents the summary point of the curve to which the pooled sensitivity and specificity correspond; the dashed line represents the 95% confidence area for the summary point; the circles represent the data from each of the included studies; and the dotted line represents the 95% confidence area in which a new relevant study will be located. SENS, sensitivity; SPEC, specificity. pretreatment method, and the cutoff level [19] . There are limited and inconclusive in vitro or in vivo data comparing the performance of different BDG assays [49, 50] . In the subgroup analyses that we performed on studies using the Fungitell or the Glucatell assay, findings seemed to be less favorable for the diagnostic accuracy of BDG testing than those of the rest of the studies.
An inherent limitation in the evaluation of diagnostic markers for IFIs lies in the absence of an accurate dichotomous reference standard. Establishing the presence of IFIs by using the EORTC/ MSG criteria is not always feasible. Some cases of true IFIs are inevitably missed, according to data from autopsy investigations [51] . Moreover, proven IFI cases often represent cases of advanced infection. For such patients, the diagnosis and treatment of IFIs may not alter the clinical course [8] . In this context, we compared in our primary analysis patients with proven or probable IFI with patients without IFI.
We did not include patients with possible IFIs as case patients, although they represent a great number of patients in routine clinical practice and the main value of BDG testing would be to correctly reclassify a subset of them as having probable IFIs. Not all of these patients have true IFIs, however [20, 28] . We noted substantial variability in the rate of BDG positivity for patients with possible IFIs among the included studies providing relevant data. We believe that the inclusion of patients with possible IFIs as case patients would not serve the purpose of this metaanalysis to estimate the diagnostic accuracy of BDG testing in patients with true IFIs and those without IFIs.
The diagnostic performance of BDG testing for IFIs evaluated in this meta-analysis seems to be similar to that of galactomannan detection used for the diagnosis of invasive aspergillosis [13, 52] . Few studies have performed direct comparisons of the 2 tests for the diagnosis of invasive aspergillosis in the same patients. One study has favored BDG in this regard [27] and one study has favored galactomannan [39] , but most studies have not showed a considerable difference between the 2 tests [31, 37, 41, 45] . An issue that warrants additional investigation is whether the 2 tests can be used as complements to each other, as their concordance might not be too high [27, 31, 37, 38] . It is likely that for some patients with invasive aspergillosis that is not identified with galactomannan testing, BDG testing could be used to make a diagnosis more quickly [32, 37, 41] .
Certain issues regarding the clinical utility of BDG testing have not been well clarified, including the timing and the frequency of BDG testing for at-risk patients, as well as the criteria for the definition of a positive test result. Caution is also warranted in the presence of factors that could increase BDG levels for reasons other than IFI [14] , such as hemodialysis with cellulose membranes [53] , administration of human blood products (immunoglobulins or albumin) [54] , use of such antibiotics as amoxicillin-clavulanate or piperacillin-tazobactam [27, 55] , presence of serious bacterial infections [38] , use of surgical gauzes containing glucan [56] , or severe mucositis [30] . In addition, practical issues, such as the need for the allocation of trained personnel for adequate time to perform the BDG test (at least 1 h for all the steps), may be important for determining its clinical utility.
In conclusion, our meta-analysis suggests that measuring serum or plasma BDG levels has good accuracy to discriminate between patients with IFIs, mainly due to Candida or Aspergillus, and patients without IFIs, but there are important differences in the characteristics of the studies that we analyzed. In clinical practice, proper use of the test would require good knowledge of its characteristics, particularly the fungal pathogens that it does not detect and the factors associated with a false-positive test result. Some issues regarding the optimal utilization of BDG testing necessitate further evaluation, such as the optimal sampling strategy for patients at risk, the criteria to define a positive test result, the optimal cutoff value, and the influence of concurrent bacteremia on diagnostic performance.
